Format

Send to

Choose Destination
See comment in PubMed Commons below
Antiviral Res. 2016 Apr;128:57-62. doi: 10.1016/j.antiviral.2016.02.005. Epub 2016 Feb 10.

Lactimidomycin is a broad-spectrum inhibitor of dengue and other RNA viruses.

Author information

1
Harvard Medical School, Department of Microbiology and Immunobiology, 77 Avenue Louis Pasteur, Boston, MA 02115, USA.
2
Harvard Medical School, Department of Microbiology and Immunobiology, 77 Avenue Louis Pasteur, Boston, MA 02115, USA. Electronic address: Priscilla_yang@hms.harvard.edu.

Abstract

Dengue virus, a member of the Flaviviridae family, is a mosquito-borne pathogen and the causative agent of dengue fever. Despite the nearly 400 million new infections estimated annually, no vaccines or specific antiviral therapeutics are currently available. We identified lactimidomycin (LTM), a recently established inhibitor of translation elongation, as a potent inhibitor of dengue virus 2 infection in cell culture. The antiviral activity is observed at concentrations that do not affect cell viability. We show that Kunjin virus and Modoc virus, two other members of the Flavivirus genus, as well as vesicular stomatitis virus and poliovirus 1, are also sensitive to LTM. Our findings suggest that inhibition of translation elongation, an obligate step in the viral replication cycle, may provide a general antiviral strategy against fast-replicating RNA viruses.

KEYWORDS:

Antiviral; Broad spectrum; Dengue virus; Host-targeted antiviral; Lactimidomycin; Translation inhibitor

PMID:
26872864
PMCID:
PMC4850914
DOI:
10.1016/j.antiviral.2016.02.005
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center